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Microdeletions within chromosome 22q11.2 cause a variable phenotype, including DiGeorge syndrome (DGS) and velocardiofacial
syndrome (VCFS). About 97% of patients with DGS/VCFS have either a common recurrent ~3 Mb deletion or a smaller, less common,
~1.5 Mb nested deletion. Both deletions apparently occur as a result of homologous recombination between nonallelic ﬂanking low-
copy repeat (LCR) sequences located in 22q11.2. Interestingly, although eight different LCRs are located in proximal 22q, only a few
cases of atypical deletions utilizing alternative LCRs have been described. Using array-based comparative genomic hybridization
(CGH) analysis, we have detected six unrelated cases of deletions that are within 22q11.2 and are located distal to the ~3 Mb common
deletion region. Further analyses revealed that the rearrangements had clustered breakpoints and either a ~1.4 Mb or ~2.1 Mb recurrent
deletion ﬂanked proximally by LCR22-4 and distally by either LCR22-5 or LCR22-6, respectively. Parental ﬂuorescence in situ hybrid-
ization (FISH) analyses revealed that none of the available parents (11 out of 12 were available) had the deletion, indicating de novo
events. All patients presented with characteristic facial dysmorphic features. A history of prematurity, prenatal and postnatal growth
delay, developmental delay, and mild skeletal abnormalities was prevalent among the patients. Two patients were found to have a car-
diovascular malformation, one had truncus arteriosus, and another had a bicuspid aortic valve. A single patient had a cleft palate. We
conclude that distal deletions of chromosome 22q11.2 between LCR22-4 and LCR22-6, although they share some characteristic features
with DGS/VCFS, represent a novel genomic disorder distinct genomically and clinically from the well-known DGS/VCF deletion
syndromes.Interstitial deletions of chromosome 22q11.2 comprise the
most commonmicrodeletion in humans and occur at a fre-
quency of approximately 1:4000–1:8000 live births.1 The
well-characterized 22q11.2 deletion syndrome is associ-
ated with a wide array of clinical phenotypes including
velocardiofacial syndrome (VCFS [MIM 192430]) and
DiGeorge syndrome (DGS [MIM 188400]).2 Individuals
with the 22q11.2 deletion can have a range of ﬁndings, in-
cluding cardiovascular malformations consisting predomi-
nantly of conotruncal heart anomalies, palatal abnormali-
ties, characteristic facial dysmorphic features, learning
difﬁculties, immune deﬁciency, congenital hypocalcemia,
and urogenital abnormalities.2–4
About 90% of patients with the 22q11.2 microdeletion
have a common ~3 Mb deletion, whereas 7% of the pa-
tients have a smaller, nested ~1.5 Mb recurrent deletion.5
Both the ~3 Mb and the ~1.5 Mb deletions were found to
occur as a result of nonallelic homologous recombination
(NAHR),6 utilizing low-copy repeat (LCR) sequences lo-
cated in the 22q11.2 region as recombination substrates.7,8
This mechanism of rearrangement explains not only the
clustered breakpoints and existence of a common recur-
rent rearrangement among patients with chromosome
22q11.2 deletion, but also the high prevalence of de
novo deletions.9 Proximal 22q contains eight LCRs known214 The American Journal of Human Genetics 82, 214–221, Januaryas LCR22s (Figure 1).8,10 On the basis of the architecture of
the 22q11.2 region, it was anticipated that other rearrange-
ments—utilizing distinct LCRs as recombination sub-
strates and leading to different recurrent deletions—might
occur in the genomic region.
The structure of LCR22-4, LCR22-5, and LCR22-6 have
been extensively studied recently11 and revealed the exis-
tence of a BCRLmodule in each LCR, suggesting a potential
substrate for NAHR-mediated rearrangement in the distal
22q11.2. However, to date, only a limited number of ‘‘atyp-
ical’’ deletions in 22q11.2 have been reported. Most of
these deletions were found to be located within the com-
mon ~3 Mb deletion region or to overlap with it.12–19
Only a few ‘‘atypical’’ deletions were found to be located
distally to the common deletion region.11,19–22 These distal
deletions with the exception of one were detected among
patients with clinical presentations related to DGS/VCFS
and therefore are subject to ascertainment bias. Not sur-
prising, therefore, is the fact that three out of the four pre-
viously described de novo cases of 22q11.2 distal deletions
and the two index cases of the affected families presented
with cardiovascular defect. Cardiac phenotype has not
been detected among the three affected relatives of the
familial index cases, implying that cardiac phenotype
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Figure 1. Schematic Overview of the
22q11.2 Region
Numbers below the schematic represent
distance (million base units) from the 22p
telomere according to NCBI human genome
build 36 (2006). LCRs are depicted as gray
boxes and labeled according to their num-
ber. LCR22-7 and LCR22-8 are located telo-
meric to the scheme and are not shown.
The BAC clones that are included in the
array-based CGH are depicted as horizontal
black lines. Boxes below the map depict
the typical deletions in DGS/VCFS and the
different distal deletions reported in pa-
tients by this study and in previous reports
(ref.). Note that exact deletion borders are
sometimes only estimated in previously
reported cases as well as in patient 3.distal deletion. However, given that there is no overlap of
the genomic intervals between the common DGS/VCFS
deletion and the 22q11.2 distal deletions, a similar pheno-
type shared by these two groups is not obvious. Indeed,
searching for ‘‘atypical’’ deletions among patients with
‘‘atypical’’ VCFS (patients that did not have the facial phe-
notype typical for DGS/VCFS but manifested with malfor-
mations and/or developmental delay) identiﬁed distal
deletions (both within and distal to the DGS/VCFS) in
about 5%. Distal deletions have not been detected among
273 patients with conotruncal heart defects.19
We implemented array-based comparative genomic
hybridization (CGH) analyses in > 8000 cases of individ-
uals with suspected chromosomal aberrations23 (and un-
published data). The targeted microarrays were designed
to cover all the telomeres at 1 Mb interval up to 10 Mb,
one bacterial artiﬁcial chromosome (BAC) at every chro-
mosome band, over 150 potential microdeletion or micro-
duplication syndromes, and their ﬂanking regions. For
detailed information regarding loci covered, see the BCM
website listed in the Web Resources. The arrays were man-
ufactured and analyzed with a protocol described previ-
ously.24 Sixty patients were identiﬁed with rearrangement
in the 22q11.2 region. Thirty-three patients (55%) had
a ~3 Mb deletion, one had a ~1.5 Mb deletion, one had
a ~4 Mb deletion, and six (10%) had deletions distal to
the DGS/VCFS common region. Ten (17%) were identiﬁed
to have a ~3 Mb duplication, and 9 (15%) had atypical du-
plications within and distal to the common DGC/VCFS
critical region.25 As stated above, in six unrelated cases,
the analyses revealed a loss in the 22q11.2 region detected
with the same two BAC clones, RP11-36N5 and RP11-
296H20 (Figure 1). These clones are located in the proxi-
mal long arm of chromosome 22 (22q11.2) just distal to
the common ~3 Mb DGS/VCFS interval. No copy-number
variation of any of the ﬁve BAC clones located within the
recurrent DGS/VCFS ~3 Mb region was detected by the ar-
ray-based CGH among these six patients. The array-based
CGH conﬁrmed the previously known diagnosis ofThe A47,XYY karyotype in patient 1. No other abnormalities
have been found by targeted array-based CGH. Fluores-
cence in situ hybridization (FISH) analyses using BAC
clone RP11-36N5 or RP11-296H20 conﬁrmed a loss at
22q11.2 in all six patients (Figure 2). Furthermore, FISH
analysis using the same probes on the parental samples
from each of the eleven available parents showed no evi-
dence of a deletion (Figure 2), indicating a de novo dele-
tion in at least ﬁve cases and potentially in the sixth.
The six patients were found to share similar clinical fea-
tures as well as physical ﬁndings (Table 1, Figure 3). Five of
the patients were born prematurely and the sixth was born
during the 38th week of gestation. Birth weight of four
patients was below the 5th percentile for gestational age,
and the birth weight of the other two was in the 5th–10th
percentile range.26 Five of the patients had postnatal
growth restriction as well. One of those (patient 3) was di-
agnosed has having gluten enteropathy (celiac disease) on
the basis of immunological studies. However, this child
had growth delay prior to his ﬁrst gluten exposure (both
prenatal and postnatal growth delay). In addition, growth
acceleration was not observed after a gluten-free diet had
been administered. Interestingly, even the oldest patient
(patient 1), who presented with obesity at the time of diag-
nosis, had a signiﬁcant postnatal growth delay up to the
age of 6 yr. The growth acceleration of this patient may
be attributed to the mid-childhood growth acceleration
frequently seen in individuals with 47,XYY karyotype.27
A global developmental delay and/or mild mental retarda-
tion, more prominent in language, was found in four of
the six. Another patient has borderline normal develop-
ment, and one had normal development. This latter child,
however, presented with severe behavioral problems
including uncontrolled aggression. Minor skeletal abnor-
malities were found in four of the patients. These abnor-
malities included coxa valga and bowed ulnae in one
case; small distal phalanx, short and broad ﬁngernails,
and bilateral ﬁfth ﬁnger clinodactyly in another case; bilat-
eral hip dysplasia in the third case; and contractures andmerican Journal of Human Genetics 82, 214–221, January 2008 215
Figure 2. Array-CGH and FISH Findings
among Patients and Their Parents
(A) Representative array-CGH output. The
mean normalized log2(Cy3/Cy5) ratio of
each BAC is plotted on the x axis as dots
with error bars and arranged along the
vertical axis from chromosome 1 at the top
to chromosomes X and Y at the bottom.
Decreased copy number was identified for
two BAC clones, RP11-36N5 and 296H20
(marked by a red ellipse to the left of the
vertical axis), which map between LCR22-
4 and LCR22-5 on chromosome 22q11.2,
just distal to the telomeric end of the com-
mon DGS/VCFS ~3 Mb deletion.
(B) Representative FISH analysis of deletion
case. The two redfluorescence signals repre-
sent hybridization using a subtelomeric
chromosome 22q FISH probe, and the single
green signal represents the hybridization of
the RP11-36N5 clone to the normal (non-
deleted) chromosome 22. Deletions were
confirmed by FISH analyses in all the cases.
(C and D) Representative FISH analyses of
normal parents. Metaphase FISH analysis
using the same probes detected two normal
copies of the distal 22q11.2 probe among
the parents.brachydactyly in the fourth. One patient had a cleft palate,
and another one was found to have a high arched palate
without cleft. Two of the patients had a cardiac defect.
One of them (patient 2) had truncus arteriosus and was
tested for DGS/VCFS due to the combination of conotrun-
cal heart defect and dysmorphic features. However, FISH
analysis did not reveal a deletion in the DGS/VCFS critical
region. Another patient had a bicuspid aortic valve, with-
out other structural heart defects (patient 3). This type of
heart defect has not been reported to be associated with
DGS/VCFS. Echocardiogram was performed in three of
the four other cases and did not detect any structural
abnormalities. Neonatal hypocalcemia, neonatal seizures,
or immunodeﬁciency was not described among any pa-
tient with 22q11.2 distal deletion (in contrast to 77% of
the patients with DGS). One of our patients, but none of
the previously described cases with 22q11.2 distal deletion,
had a history of cleft palate, a common ﬁnding among
patients with DGS/VCFS.
Physical examination of all of the six patients revealed
characteristic multiple dysmorphic facial features (Table 1,
Figure 3). The common facial dysmorphic features included
arched eyebrows, deep-set eyes, a smooth philtrum, a thin
upper lip, hypoplastic alae nasi, and a small, pointed chin.
In order to more precisely map breakpoints of the
22q11.2 deletion and to further explore the molecular
mechanism for the deletion, we performed higher-resolu-
tion genomic analysis in ﬁve of the cases by using high-
density array-based oligonucleotide CGH (Agilent 244K
Whole Human Genome Oligo Microarray Kit, Agilent216 The American Journal of Human Genetics 82, 214–221, JanuaryTechnologies, CA, USA) according to the manufacturer’s
recommendations. The array-based oligonucleotide CGH
revealed that patients 1 and 2 had a ~2.1 Mb deletion
located between LCR22- 4 and LCR22-6. The deletion
size in cases 3, 4, and 6 was found to be ~1.4 Mb and spans
the genomic region between LCR22-4 and LCR22-5 (Fig-
ure 4). The high-resolution array analyses revealed that
all ﬁve patients shared a proximal breakpoint. The two
patients with the ~2.1 Mb deletion and the three patients
with the nested ~1.4 Mb deletion shared the same distal
breakpoint as well. The three breakpoints coincided with
LCR22-4, LCR22-5, and LCR22-6 (based on the sequence
data from the genome browser). The parents of patient
ﬁve did not consent to the Agilent 244K array, and there-
fore in this case we have used the BCR probe, which
maps between LCR22-5 and LCR22-6, for FISH analysis.
The patient was found to have two copies of the BCR
probe, suggesting that the LCR22-5 to LCR22-6 segment
was not deleted in this case.
A review of the literature reporting 22q11.2 distal dele-
tions revealed that three of the previously described cases
had, similar to our cases, de novo deletions of the LCR22-
4 to LCR22-5 segment or the LCR22-4 to LCR22-6 seg-
ment,19,21,22 implying a pathogenic role for such deletions.
A fourth case20 with the LCR22-4 to LCR22-6 segment de-
letion was found to be part of an affected family with mul-
tiple affected individuals and a variable phenotype. The
deletion found in the ﬁfth previously described case19
was smaller (~0.7 Mb), located between the LCR22-5 and
LCR22-6 segment, and did not include the ~1.4 Mb2008
Table 1. Clinical and Cytogenetic Finding among Six Patients with 22q11.2 Distal Deletion
Manifestation Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 6 Total
22q11.2 deletion size
(Mb)
~2.1 ~2.1 ~1.4 ~1.4 ~1.4* ~1.4
LCR involved 4–6 4–6 4–5 4–5 4–5* 4–5
Karyotype 47,XYY 46,XY 46,XY 46,XY 46,XX 46,XY
Parental FISH P-Nl, M-Nl P-Nl, M-Nl P-Nl, M-Nl P-?, M-Nl P-Nl, M-Nl P-Nl, M-Nl 11-Nl, 1-?
Gender M M M M F M 4M/1F
Age (years) 11 3 6 5 3 4
Gestational age (weeks) 32 33 38 36 35 37
Birth weight(centile) 1050 (3%) 1360(3%–10%) 2210(3%–10%) 1250 (< < 3%) 1700 (< < 3%)
Postnatal growth
retardation
þ þ þ  þ þ 5/6
Weight at presentation 97% <5% < < 5% 60% < < 5% < < 5%
Height at presentation
(centile)
20% <5% ? 60% < < 5% < < 5%
Developmental delay þ þ þ  þ/ þ 4/6
Behavioral problems þ   þ   2/6
Cardiovascular defect
(type)
þ (truncus arteriosus) þ (bicuspid aortic valve)    2/6
Smooth philtrum þ þ þ þ þ þ 6/6
Cleft palate þ      1/6
Arched eye brows þ þ  þ þ 4/5
Pointed chin  þ þ  þ 3/5
Skeletal abnormalities þ   þ  þ 3/6
High arched palate  þ     1/6
Deep-set eyes   þ  þ þ 3/6
Hypoplastic alae nasi  þ þ  þ þ 4/6
Recurrent infections       0/6
*Exact deletion size is estimated on the basis of array CGH, FISH results, and the known genomic architecture. P denotes paternal, M denotes maternal, and
Nl denotes normal.LCR22-4 to LCR22-5 segment, a genomic segment that was
deleted in all of the other previously reported cases and in
all of our cases. This patient had a congenital heart defect
and normal appearance and psychomotor development.
Only very careful investigation revealed minimal dysmor-
phic features. This deletion was also detected in the pat-
ent’s healthy father, who had narrow palpebral ﬁssures
and mildly low-set ears. Interestingly, recently eight indi-
viduals with the BCR deletion (located within LCR22-5
and LCR22-6 interval used as a control probe for chromo-
some 22) have been detected from among 11,688 individ-
uals that were referred for evaluation of subtelomeric rear-
rangements.28 All of these individuals had an intact DGS/
VCFS region, but the size of the deletions has not been eval-
uated and the phenotype was not described in detail.
Clinically, many microdeletion syndromes not only
show a high degree of variability among patients with
identical deletions29 but also share many common fea-
tures. Features such as developmental and growth delay,
multiple congenital anomalies, and a wide range of dys-
morphic features are common inmany chromosomal aber-
rations. Nevertheless, several features of 22q11.2 distal
deletion between LCR22-4 and LCR22-6 were shared by
the majority of our patients (Table 1), most are distinctive
from those observed in DGS/VCFS, and some are character-
istic features associated with deletion of a common geno-
mic interval. Prenatal and postnatal growth restriction,
for example, was observed in 83% of our patients. WhereasThe Amgrowth restriction is a common feature of chromosomal
aberration, many syndromes show no growth restriction
or only postnatal growth restriction. Prenatal growth
restriction has not been widely described in most patients
with DGS/VCFS, and postnatal growth restriction has been
described in only about 36% of the patients. Developmen-
tal delay and/or mental retardation appear more common
among patients with distal 22q11.2 deletion compared
with patients having DGS/VCFS. Similarly, skeletal abnor-
malities among patients with distal 22q11.2 deletion are
not only more common than those described among pa-
tients with DGS/VCFS,30 but are also different in nature.
The typical facial dysmorphic features of patients with
22q11.2 distal deletion are characteristic and do not resem-
ble those of patients with DGS/VCFS.27
Although prematurity is not a common feature of chro-
mosomal aberration, and has not been described as part of
DGS/VCFS, at least four of our six patients were born pre-
maturely (between 32 and 36 weeks of gestation), the ﬁfth
was born during or after the 37th week of gestation, and the
sixth was born during the 38th week of gestation. Given
that our cohort is small, there is still a ﬁnite probability
that the prematurity among our patients happened by
chance. The probability of such a random event is low be-
cause the percentage of preterm births (<37 completed
weeks of gestation) in the United States is about 12.7%.31
Trisomy 18 is the only other chromosomal syndrome
that has been described to be associated with prematurityerican Journal of Human Genetics 82, 214–221, January 2008 217
to date. However, the average gestational age at birth of
such newborns was calculated to be 38 weeks,32 a distinctly
longer term than the average of 35.2 weeks in our patients.
This observation may imply the presence of a dosage-sen-
sitive gene that is associated with prematurity and/or low
birth weight and is located within the distal 22q11.2 re-
Figure 3. Facial Appearance of Patients with 22q11.2 Distal
Deletions
Shared facial dysmorphic features include arched eyebrows, flat-
tened midface, smooth philtrum, and thin upper lip. (A) Patient 1,
whose ~2.1 Mb deletion extends from LCR22-4 through LCR22-6.
Note the arched eyebrows and the smooth philtrum. This patient
also has sex-chromosome aneuploidy with 47,XYY karyotype.
(B and C) Patient 2, with ~2.1 Mb deletion. Note the low-set,
cuboidal ears, hypoplastic browridges, broad nasal bridge, smooth
philtrum, and pointed chin.
(D) Patient 5, whose ~1.4 Mb deletion extends from LCR 22-4
through LCR22-5. Note the pointed chin in addition to partial ptosis.
(E and F) Patient 6, with ~1.4 Mb deletion. Note the arched
eyebrows, hypoplastic browridges, smooth philtrum, and flat re-
tracted midface.218 The American Journal of Human Genetics 82, 214–221, Januarygion. Interestingly, one of the genes located in the deleted
region, mitogen-activated protein kinase 1 (MAPK1) may
be associated with placental development and low birth
weight. MAPK1 has a role in one of the four mitogen-acti-
vated protein kinase cascades. Knockout studies of a few
genes in these cascades, including MAPK1, revealed some
associations with abnormal placental development, lead-
ing to intrauterine growth restriction and intrauterine
death of null mice.33
Although congenital heart defects are common in many
chromosomal aberrations, the fact that one of our six pa-
tients in addition to one of the four previously described
de novo cases and one member of the familial case with
22q11.2 distal deletion had a very speciﬁc cardiac defect,
truncus arteriosus, is intriguing. This high percentage of
truncus arteriosus in 22q11.2 distal deletion may be par-
tially due to ascertainment bias of the previously described
cases; nevertheless, distal 22q11.2 may be associated with
an increased risk of truncus arteriosus. In fact, although
truncus arteriosus is one of themost characteristic heart de-
fects in DGS/VCFS, it exists in only 7% of such patients.34
Truncus arteriosus has not been described yet as a common
ﬁnding in any other chromosomal aberration or single-
gene defect. About one-third of patients with such a cardiac
defect have one of the two more common ~1.5 Mb or
~3 Mb 22q11.2 recurrent deletions,35,36 but a systematic
analysis of other genomic disorders leading to truncus arte-
riosus in a large number of patients has not been per-
formed. The fact that such a rare heart defect is common
in two adjacent but nonoverlapping microdeletion syn-
dromes (DGS/VCFS and 22q11.2 distal deletion), and the
fact that this heart defect has not been described com-
monlywith other chromosomal aberration,might be a ran-
domﬁnding. An alternative explanation is a position effect
of the distal deletion on a gene located in the DGS/VCFS
or vice versa responsible for this overlapping cardiac
phenotype.37,38 Another explanation for this sharedFigure 4. Analysis of 22q11.2-Distal-
Deletion Breakpoints by High-Resolu-
tion Oligonucleotide Microarray Analysis
Results of Agilent 244K array-based oligo-
nucleotide CGH performed on DNA samples
from patients 1, 2, and 5 and 6 revealed
similar proximal breakpoints in all of the
cases. Red arrows represent the known
LCR22s in the region. Black horizontal lines
represent the different breakpoints, and
the numbers represent genomic distance
of the different breakpoints (Megabase
units) from 22p telomere according to
NCBI human genome build 36 (2006).
Note that the proximal breakpoint is com-
mon in all of the cases, and the distal
breakpoints also coincide for patients
1 and 2 and patients 5 and 6, respectively.
The breakpoints are located in the known
LCR22s, implying NAHR-based recombina-
tion mechanism.2008
phenotype could be clustering of genes involved in the
development of heart in this genomic region.
Given that three de novo cases and one familial case
(with three affected individuals) have been reported with
LCR22-4 to LCR22-6 deletions, we have examined the
characteristic phenotype of 22q11.2 distal deletion among
these patients. Unfortunately, birth weight, indicating
prenatal growth restriction, has been reported in only
one-sixth of them (and was normal for gestational age).22
However, height at presentation was reported among
one-third of the de novo cases and two-thirds of individ-
uals from the affected family.20,22 In all of them, the height
was reported to be at the 10th centile. Another previously
described case reported short stature.21 These data imply
that postnatal growth restriction and short stature are com-
mon features of this syndrome. Information regarding the
gestational age at birth was provided for only two of the
previously described cases. Both childrenwere born prema-
turely after 35 weeks of gestation.21,22 Congenital heart de-
fects and palate abnormalities were prevalent among previ-
ously described cases with higher prevalence than among
our patients, in part because of to ascertainment bias. Sim-
ilar to our patients, learning difﬁculties and/or psychomo-
tor developmental delay was prevalent among themajority
of the previous described cases. The overall data suggest,
however, that severe mental retardation is not common
among patients with 22q11.2 distal deletion. On the basis
of on available photographs and clinical description of
published cases, it seems that most of them share the char-
acteristic facial features of 22q11.2 distal deletion. Two pre-
viously described patients19,20 had choanal atresia and/or
stenosis, and one had immunodeﬁciency.20 Such pheno-
types have not been detected among our patients and
may be subject to ascertainment bias because these features
are prevalent in DGS/VCFS27 and were even part of the
inclusion criteria in one of the previous study.19
On the basis of oligonucleotide array-CGH analysis (Fig-
ure 4) and information obtained from the NCBI genome
(build 36, 2006), it is apparent that 22q11.2 distal deletions
involve segments that extend between known LCRs:
LCR22-4 to LCR22-5 or LCR22-6. Recent investigation of
LCR22-5 and LCR22-6 structure and organization11 re-
vealed that both include BCRL-containing modules and
that LCR22-5 includes a GGTL-containing module as well.
Both modules are part of LCR22-4 structure.7 In all of the
cases that were analyzedwith a high-resolution oligonucle-
otidemicroarray, breakpoint analyses revealed similar junc-
tions. This breakpoint is located in the proximal part of the
three relevant LCR22s: LCR22-4, LCR22-5, and LCR22-6
(Figure 4). This proximal portion of these LCRs contains
the BCRL module in all of them.7,11 This ﬁnding implies
not only that these LCRs have a role in the mechanism of
the rearrangement byNAHRbut also that the BCRLmodule
speciﬁcally may be utilized as a substrate in NAHR causing
22q11.2 distal deletions. The fact that de novo rearrange-
ments were found in the great majority of 22q11.2 distal
deletions supports the role of NAHR in these deletions,The Abecause one would expect to ﬁnd a high rate of de novo
arrangement in regions that have high genome complexity
and are subjected to NAHR.39
We could not detect a clear difference in the severity or
the phenotype between the larger ~2.1 Mb deletion and
the smaller nested ~1.4 Mb deletion. However, more
patients must be characterized in order to determine
whether a phenotypic difference exists between these
two sizes of deletion. Molecularly, the ~1.4 Mb LCR22-4
to LCR22-5 segment contains at least 17 annotated genes,
and the ~0.7 Mb LCR22-5 to LCR22-6 contains at least four
additional genes. Many of the genes in this genomic region
have not been extensively studied. We do not know yet
which of the genes in this region are sensitive to the dosage
effect generated by the copy-number variation due to the
deletion or the potential inﬂuence of such a dosage effect.
In conclusion, 22q11.2 distal deletion is a recurrent mi-
crodeletion syndrome likely to result from NAHR. This
newly recognized genomic disorder has speciﬁc character-
istics including prematurity, prenatal and postnatal
growth restriction, learning difﬁculties and/or develop-
mental delay, characteristic facial features, skeletal abnor-
malities, and increased incidence of a speciﬁc type of
heart defect, truncus arteriosus. The phenotype is, in
many ways, distinct from the phenotype of the adjacently
located microdeletion syndrome DGS/VCFS. The two
cytogenetically and clinically distinctive syndromes share
an overlapping cardiac phenotype. We suggest, therefore,
that individuals with the characteristic features of
22q11.2 LCR22-4 to LCR22-6 deletion and patients with
a less suggestive DGS/VCFS phenotype and negative
DGS/VCFS FISH results, as well as every individual with
truncus arteriosus, should be tested for the 22q11.2 distal
deletion. However, given that dysmorphic features, short
stature, heart defects, and developmental delay are com-
mon ﬁndings in many chromosomal aberrations, array
CGH23,39 is currently the most efﬁcient and cost-effective
means of testing for submicroscopic chromosomal aberra-
tions associated with genomic disorders.
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Web Resources
The URLs for data presented herein are as follows:
Genome Browser, http://genome.ucsc.edu/cgi-bin/hgGateway
OMIM, http://www.ncbi.nlm.nih.gov/Omim/ (for DiGeorge
syndrome and velocardiofacial syndrome)
BCM, http://www.bcm.edu/cma/table.htm
References
1. Scambler, P.J. (2000). The 22q11 deletion syndromes. Hum.
Mol. Genet. 9, 2421–2426.merican Journal of Human Genetics 82, 214–221, January 2008 219
2. Ryan, A.K., Goodship, J.A., Wilson, D.I., Philip, N., Levy, A.,
Seidel, H., Schuffenhauer, S., Oechsler, H., Belohradsky, B.,
Prieur, M., et al. (1997). Spectrum of clinical features associ-
ated with interstitial chromosome 22q11 deletions: A Euro-
pean collaborative study. J. Med. Genet. 34, 798–804.
3. Shprintzen, R.J., Goldberg, R.B., Lewin, M.L., Sidoti, E.J., Berk-
man, M.D., Argamaso, R.V., and Young, D. (1978). A new
syndrome involving cleft palate, cardiac anomalies, typical
facies, and learning disabilities: velo-cardio-facial syndrome.
Cleft Palate J. 15, 56–62.
4. Emanuel, B.S., McDonald-McGinn, D., Saitta, S.C., and Zackai,
E.H. (2001). The 22q11.2 deletion syndrome. Adv. Pediatr. 48,
39–73.
5. Carlson, C., Sirotkin, H., Pandita, R., Goldberg, R., McKie, J.,
Wadey, R., Patanjali, S.R., Weissman, S.M., Anyane-Yeboa, K.,
Warburton, D., et al. (1997). Molecular deﬁnition of 22q11
deletions in 151 velo-cardio-facial syndrome patients. Am.
J. Hum. Genet. 61, 620–629.
6. Stankiewicz, P., and Lupski, J.R. (2002). Genome architecture, re-
arrangements and genomic disorders. Trends Genet. 18, 74–82.
7. Shaikh, T.H., Kurahashi, H., Saitta, S.C., O’Hare, A.M., Hu, P.,
Roe, B.A., Driscoll, D.A., McDonald-McGinn, D.M., Zackai,
E.H., Budarf, M.L., and Emanuel, B.S. (2000). Chromosome
22-speciﬁc low copy repeats and the 22q11.2 deletion
syndrome: Genomic organization and deletion endpoint
analysis. Hum. Mol. Genet. 9, 489–501.
8. Edelmann, L., Pandita, R.K., Spiteri, E., Funke, B., Goldberg, R.,
Palanisamy, N., Chaganti, R.S., Magenis, E., Shprintzen, R.J.,
and Morrow, B.E. (1999). A common molecular basis for rear-
rangement disorders on chromosome 22q11. Hum. Mol.
Genet. 8, 1157–1167.
9. Wilson, D.I., Goodship, J.A., Burn, J., Cross, I.E., and Scambler,
P.J. (1992). Deletions within chromosome 22q11 in familial
congenital heart disease. Lancet 340, 573–575.
10. McDermid, H.E., and Morrow, B.E. (2002). Genomic disorders
on 22q11. Am. J. Hum. Genet. 70, 1077–1088.
11. Shaikh, T.H., O’Connor, R.J., Pierpont, M.E., McGrath, J.,
Hacker, A.M., Nimmakayalu, M., Geiger, E., Emanuel, B.S.,
and Saitta, S.C. (2007). Low copy repeats mediate distal chro-
mosome 22q11.2 deletions: Sequence analysis predicts break-
point mechanisms. Genome Res. 17, 482–491.
12. Amati, F., Conti, E., Novelli, A., Bengala,M., Diglio,M.C., Mar-
ino, B., Giannotti, A., Gabrielli, O., Novelli, G., and Dallapic-
cola, B. (1999). Atypical deletions suggest ﬁve 22q11.2 critical
regions related to the DiGeorge/velo-cardio-facial syndrome.
Eur. J. Hum. Genet. 7, 903–909.
13. Kurahashi, H., Tsuda, E., Kohama, R., Nakayama, T., Masuno,
M., Imaizumi, K., Kamiya, T., Sano, T., Okada, S., and Nish-
isho, I. (1997). Another critical region for deletion of 22q11:
A study of 100 patients. Am. J. Med. Genet. 72, 180–185.
14. O’Donnell, H., McKeown, C., Gould, C., Morrow, B., and
Scambler, P. (1997). Detection of an atypical 22q11 deletion
that has no overlap with the DiGeorge syndrome critical
region. Am. J. Hum. Genet. 60, 1544–1548.
15. Garcia-Minaur, S., Fantes, J., Murray, R.S., Porteous,M.E., Strain,
L., Burns, J.E., Stephen, J., andWarner, J.P. (2002). A novel atyp-
ical 22q11.2 distal deletion in father and son. J. Med. Genet. 39,
E62.
16. McQuade, L., Christodoulou, J., Budarf,M., Sachdev, R.,Wilson,
M., Emanuel, B., and Colley, A. (1999). Patient with a 22q11.2
deletion with no overlap of the minimal DiGeorge syndrome
critical region (MDGCR). Am. J. Med. Genet. 86, 27–33.220 The American Journal of Human Genetics 82, 214–221, January17. Kerstjens-Frederikse, W.S., Kurahashi, H., Driscoll, D.A.,
Budarf, M.L., Emanuel, B.S., Beatty, B., Scheidl, T., Siegel-Bar-
telt, J., Henderson, K., Cytrynbaum, C., et al. (1999). Microde-
letion 22q11.2: Clinical data and deletion size. J. Med. Genet.
36, 721–723.
18. Levy, A., Demczuk, S., Aurias, A., Depetris, D., Mattei, M.G.,
and Philip, N. (1995). Interstitial 22q11microdeletion exclud-
ing the ADU breakpoint in a patient with DiGeorge syndrome.
Hum. Mol. Genet. 4, 2417–2419.
19. Rauch, A., Zink, S., Zweier, C., Thiel, C.T., Koch, A., Rauch, R.,
Lascorz, J., Huffmeier, U., Weyand, M., Singer, H., and Hof-
beck, M. (2005). Systematic assessment of atypical deletions
reveals genotype-phenotype correlation in 22q11.2. J. Med.
Genet. 42, 871–876.
20. Rauch, A., Pfeiffer, R.A., Leipold, G., Singer, H., Tigges, M., and
Hofbeck, M. (1999). A novel 22q11.2 microdeletion in
DiGeorge syndrome. Am. J. Hum. Genet. 64, 659–666.
21. Saitta, S.C., McGrath, J.M., Mensch, H., Shaikh, T.H., Zackai,
E.H., and Emanuel, B.S. (1999). A 22q11.2 deletion that
excludes UFD1L and CDC45L in a patient with conotruncal
and craniofacial defects. Am. J. Hum. Genet. 65, 562–566.
22. Mikhail, F.M., Descartes, M., Piotrowski, A., Andersson, R.,
Diaz de Stahl, T., Komorowski, J., Bruder, C.E., Dumanski,
J.P., and Carroll, A.J. (2007). A previously unrecognized micro-
deletion syndrome on chromosome 22 band q11.2 encom-
passing the BCR gene. Am. J. Med. Genet. A. 143, 2178–2184.
23. Lu, X., Shaw, C.A., Patel, A., Li, J., Cooper, M.L., Wells, W.R.,
Sullivan, C.M., Sahoo, T., Yatsenko, S.A., Bacino, C.A., et al.
(2007). Clinical implementation of chromosomal microarray
analysis: Summary of 2513 postnatal cases. PLoS ONE 2, e327.
24. Cai, W.W., Mao, J.H., Chow, C.W., Damani, S., Balmain, A.,
and Bradley, A. (2002). Genome-wide detection of chromo-
somal imbalances in tumors using BAC microarrays. Nat.
Biotechnol. 20, 393–396.
25. Ou, Z., Berg, J.S., Yonath, H., Enciso, V.B., Miller, D.T., Picker,
J., Lenzi, T., Keegan, C.E., Sutton, V.R., Belmont, J., et al. Mi-
croduplications of 22q11.2 are frequently inherited and are
associated with variable phenotypes. Genet. Med., in press.
26. Fenton, T.R. (2003). A new growth chart for preterm babies:
Babson and Benda’s chart updated with recent data and
a new format. BMC Pediatr. 3, 13.
27. Jones, K.L. (2006). Smith’s Recognizable Patterns of Human
Malformation, Volume 6 (Philadelphia, PA: Elsevier Saunders).
28. Ravnan, J.B., Tepperberg, J.H., Papenhausen, P., Lamb, A.N.,
Hedrick, J., Eash, D., Ledbetter, D.H., and Martin, C.L. (2006).
Subtelomere FISH analysis of 11 688 cases: An evaluation of
the frequency and pattern of subtelomere rearrangements in
individuals with developmental disabilities. J. Med. Genet.
43, 478–489.
29. Potocki, L., Shaw, C.J., Stankiewicz, P., and Lupski, J.R. (2003).
Variability inclinical phenotypedespite commonchromosomal
deletion in Smith-Magenis syndrome. Genet. Med. 5, 430–434.
30. Ming, J.E., McDonald-McGinn, D.M., Megerian, T.E., Driscoll,
D.A., Elias, E.R., Russell, B.M., Irons,M., Emanuel, B.S., Marko-
witz, R.I., and Zackai, E.H. (1997). Skeletal anomalies and
deformities in patients with deletions of 22q11. Am. J. Med.
Genet. 72, 210–215.
31. Hamilton, B.E., Minino, A.M., Martin, J.A., Kochanek, K.D.,
Strobino, D.M., and Guyer, B. (2007). Annual summary of
vital statistics: 2005. Pediatrics 119, 345–360.
32. Goc, B., Walencka, Z., Wloch, A., Wojciechowska, E., Wiecek-
Wlodarska, D., Krzystolik-Ladzinska, J., Bober, K., and2008
Swietlinski, J. (2006).Trisomy18inneonates:Prenataldiagnosis,
clinical features, therapeutic dilemmas and outcome. J. Appl.
Genet. 47, 165–170.
33. Aouadi, M., Binetruy, B., Caron, L., Le Marchand-Brustel, Y.,
and Bost, F. (2006). Role of MAPKs in development and dif-
ferentiation: Lessons from knockout mice. Biochimie 88,
1091–1098.
34. McDonald-McGinn, D.M., Kirschner, R., Goldmuntz, E., Sulli-
van, K., Eicher, P., Gerdes, M., Moss, E., Solot, C., Wang, P.,
Jacobs, I., et al. (1999). The Philadelphia story: The 22q11.2
deletion: Report on 250 patients. Genet. Couns. 10, 11–24.
35. Goldmuntz, E., Clark, B.J., Mitchell, L.E., Jawad, A.F., Cuneo,
B.F., Reed, L., McDonald-McGinn, D., Chien, P., Feuer, J.,
Zackai, E.H., et al. (1998). Frequency of 22q11 deletions in
patients with conotruncal defects. J. Am. Coll. Cardiol. 32,
492–498.The A36. Iserin, L., de Lonlay, P., Viot, G., Sidi, D., Kachaner, J., Mun-
nich, A., Lyonnet, S., Vekemans, M., and Bonnet, D. (1998).
Prevalence of the microdeletion 22q11 in newborn infants
with congenital conotruncal cardiac anomalies. Eur. J. Pediatr.
157, 881–884.
37. Lee, J.A., Madrid, R.E., Sperle, K., Ritterson, C.M., Hobson,
G.M., Garbern, J., Lupski, J.R., and Inoue, K. (2006). Spastic
paraplegia type 2 associated with axonal neuropathy and
apparent PLP1 position effect. Ann. Neurol. 59, 398–403.
38. Smyk, M., Berg, J.S., Pursley, A., Curtis, F.K., Fernandez, B.A.,
Bien-Willner, G.A., Lupski, J.R., Cheung, S.W., and Stankie-
wicz, P. (2007). Male-to-female sex reversal associated with
an approximately 250 kb deletion upstream of NR0B1
(DAX1). Hum. Genet. 122, 63–70.
39. Lupski, J.R. (2006). Genome structural variation and sporadic
disease traits. Nat. Genet. 38, 974–976.merican Journal of Human Genetics 82, 214–221, January 2008 221
